CAGE Bio Launches Phase 2b Study for CGB-500 in Immuno-Dermatology

CAGE Bio, Inc., a biotechnology firm in clinical development focusing on novel treatments for prevalent immuno-dermatological conditions, announced the start of a phase 2b dose-ranging study for its CGB-500 product. This topical JAK inhibitor cream, created with CAGE Bio’s unique ionic liquid technology, signifies a possible advancement for low body surface area (BSA), moderate to severe atopic dermatitis (AD) condition.

CGB-500 delivers medicine directly through the skin, combining high efficacy with minimal systemic exposure. Results from the 2024 phase 2a trial showed efficacy comparable to biologics, outperforming current best-in-class topical treatments while maintaining a significantly lower side-effect profile. Specifically, CGB-500 had an 8-week treatment success of 95% (IGA score of “0" or “1" and > 2 grade improvement).

This expanded phase 2b trial (n=180) aims to enhance dosing schedules and continue evaluating the safety and effectiveness of CGB-500. This crucial move highlights CAGE Bio’s dedication to meeting the unmet needs of patients with moderate to severe AD and limited body surface area (BSA) involvement, where it is essential to balance treatment speed and effectiveness with the costs of systemic exposure and potential side effects.

“CGB-500 offers a promising solution for patients seeking rapid and effective localized relief potentially avoiding systemic therapies and their associated side-effects” said Dr. Justin Ko MD, a board-certified dermatologist in San Francisco Bay Area.

“Our ionic liquid platform continues to demonstrate its potential in enabling highly effective and targeted topical therapies. With the phase 2b trial now underway, we are one step closer to transforming how atopic dermatitis is treated,” said Nitin Joshi,  CEO of CAGE Bio.